A federal appeals court has scheduled oral arguments for September in a case challenging Arkansas’ protections for 340B providers’ contract [...] …
Year: 2023
The first posted fiscal year 2023 audit of a drug maker tentatively found the company owes repayments to providers. The [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Federal officials confirmed that 340B-eligible drugs are among the 12 medications pharmaceutical manufacturer Pfizer has limited to direct purchase after [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Three provider organizations may have contract pharmacies terminated from the 340B program and 10 providers would owe repayments to drug [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The proportion of retail contract pharmacies in the 340B program that contract exclusively with “core safety-net” facilities fell from 95% [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The U.S. Department of Health and Human Services (HHS) asked a federal court to deny a preliminary injunction sought by [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drug manufacturer Pfizer is changing how healthcare providers access 340B pricing on two expensive, related heart medicines, effective Nov. 1, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Two drug manufacturers are sending 340B covered entities refunds for overcharges totaling $100 or more, according to public filings posted [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Eligible covered entities in Hawaii may enroll in the 340B program immediately rather than having to wait for the next [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The hiring of lobbyists in the congressional legislative fight over 340B was dominated by pharmaceutical firms and provider-manufacturer alliances in [...] …